UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 ~~UNDER~~

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2012

Commission File Number: 001-34564

China Nuokang Bio-Pharmaceutical Inc.

No. 18-1 East Nanping Road

Hunnan National New & High-tech Development Zone

Shenyang, Liaoning Province

People’s Republic of China 110171

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 20 6-~~F x Form 40~~K in paper as permitted by Regulation S-FT Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(17): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


China Nuokang Bio-Pharmaceutical Inc.

By:		/s/ Baizhong Xue
Name:		Baizhong Xue
Title:		Chairman and Chief Executive Officer

Date: June 5 18, 2012

Exhibit Index


Exhibit No.		Description

Exhibit 99.1		Press Release

Exhibit 99.1

China Nuokang Bio-Pharmaceutical Inc. ~~Appoints~~Announces ~~Lazard~~Change ~~and~~in ~~Houlihan~~CFO ~~Lokey as Independent Financial Advisors to Evaluate “Going Private” Proposal~~

~~Beijing~~BEIJING, June 415, 2012 ~~(Globe Newswire)~~ – China Nuokang Bio-Pharmaceutical Inc. (~~NASDAQ~~Nasdaq: NKBP) (“Nuokang” or the “Company”), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that Robert Tianruo Pu, the ~~independent~~chief ~~committee~~financial officer of the Company’s, ~~board~~has oftendered ~~directors~~his (resignation for personal reasons, effective June 30, 2012. Felix Chungfai Wong, currently the ~~“Independent~~ ~~Committee”)~~Company’s ~~has~~finance director, ~~appointed~~will ~~Lazard~~replace ~~and~~Mr. Pu ~~Houlihan~~to ~~Lokey~~serve as ~~its~~the ~~independent~~chief financial ~~advisors~~officer. Upon his resignation, Mr. Pu will remain with the Company as a consultant.

As“Mr. ~~previously~~Pu ~~announced, the~~has ~~Company’s~~made ~~board~~significant ofcontributions ~~directors formed the Independent Committee~~ to ~~review~~Nuokang’s growth and ~~evaluate~~development ~~the~~since ~~preliminary,~~he ~~non-binding~~joined ~~proposal~~in ~~that~~September ~~the~~2008. ~~board~~We ~~received~~thank onhim ~~May 10,~~for ~~2012,~~his ~~from~~leadership ~~Mr. Baizhong Xue, chairman~~ and ~~chief~~dedication ~~executive~~to ~~officer~~the ~~of Nuokang~~Company. ~~Mr. Xue~~We ~~has~~wish ~~proposed~~him ~~to acquire~~ all of the ~~outstanding~~best ~~shares~~in ofhis ~~the~~future ~~Company not currently owned~~endeavors,” ~~legally~~commented ~~or beneficially, by~~ Mr. Baizhong Xue, orthe ~~companies~~Company’s ~~controlled~~chairman byand Mrchief executive officer. ~~Xue.~~

~~The~~Felix Chungfai ~~Independent~~Wong ~~Committee~~joined isNuokang ~~considering~~in February 2012 as its finance director. Mr. ~~Xue’s~~Wong ~~proposal~~has ~~but~~three ~~has~~decades ~~not~~of ~~set~~experience ain ~~definitive~~finance, ~~timetable~~management toand ~~complete~~accounting ~~its~~in ~~evaluation~~the ~~nor~~U.S. ~~set~~and Greater China. He joined Nuokang from ITT Corporation, a ~~timetable~~ ~~for~~company ~~evaluation~~listed ofon ~~other~~the New ~~alternatives~~York ~~that~~Stock itExchange, ~~might~~where ~~receive.~~he ~~The~~held ~~Independent~~various ~~Committee~~senior ~~does~~financial ~~not~~management ~~intend~~positions. Prior to ~~announce~~that, ~~developments~~he ~~unless~~held ~~and~~various ~~until~~senior anfinance ~~agreement~~positions ~~has~~across ~~been~~a ~~reached.~~broad ~~There~~range ~~can~~of beindustries, noincluding ~~assurance~~finance ~~that~~manager ~~any~~of ~~definitive~~Roche ~~offer~~(China) ~~will~~Investment ~~be made~~Ltd., ~~that~~one ~~any~~of ~~agreement~~the world’s ~~will~~leading bepharmaceutical ~~executed,~~and ordiagnostics ~~that~~firms. He also has a ~~transaction~~decade ~~with~~of auditing experience in large multinational accounting firms in Hong Kong and Singapore. Mr. ~~Xue~~Wong orgraduated ~~any~~from ~~other~~the ~~transaction~~Accountancy ~~will~~Faculty beof ~~approved~~the orHong ~~consummated~~Kong Polytechnic University and is a member of the Hong Kong Institute of Certified Public Accountants, the Association of Chartered Certified Accountants and the Institute of Chartered Accountants in England & Wales.

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (~~NASDAQ~~Nasdaq: NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 4,200 hospitals in China. Nuokang’s principal products include (1) Baquting®, China’s leading hemocoagulase product by market share;, (2) Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis;, and ~~alpha~~(3) Alpha ~~lipoic~~Lipoic ~~acid~~Acid ~~capsules~~Capsule, or ALA, an antioxidant product that addresses diabetic neuropathy. The Company’s product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.

Safe-Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as “may,” “could,” “would,” “plan,” “anticipate,” “"believe,” “estimate,” “predict,” “potential,” “expects,” “intends” and “future” or similar expressions. Among other things, the statements relating to the ~~evaluation~~Company’s ofexpected orprogress on the ~~developments~~product ~~with~~portfolio ~~respect~~and tofuture ~~Mr. Baizhong~~financial ~~Xue’s~~results ~~proposal or any other alternative transaction~~ may contain forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management’s current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company’s control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company’s actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including those described under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.

Contact: ~~Information~~

China Nuokang Bio-Pharmaceutical Inc. Mr. Steven Duan Vice President of Investor Relations Email: dsz@nkbp.com ICR, Inc. Mr. Rob Koepp Tel: (+86) 10-6583-7516 or (646) 405-5180 Email: robert.koepp@icrinc.com

Mr. Steven Duan

Vice President of Investor Relations

Email: dsz@nkbp.com

ICR, Inc.

Mr. Rob Koepp

Tel: (+86) 10-6583-7516 or (646) 405-5180

Email: robert.koepp@icrinc.com

Filing Compare · China Nuokang Bio-Pharmaceutical Inc.